An increase in viral replicative capacity drives the evolution of protease inhibitor-resistant human immunodeficiency virus type 1 in the absence of drugs

Journal of Acquired Immune Deficiency Syndromes

Volumn 42, Issue 2, 2006, Pages 162-168

  Van Maarseveen, Noortje M ^a   De Jong, Dorien ^a   Boucher, Charles A B ^a   Nijhuis, Monique ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Evolution; Protease; Replicative capacity; Resistance

Indexed keywords

PROTEINASE INHIBITOR; RITONAVIR;

ARTICLE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MUTATION; NONHUMAN; PRIORITY JOURNAL; VIRUS; VIRUS REPLICATION; WILD TYPE;

AMINO ACID SUBSTITUTION; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION, MISSENSE; VIRUS REPLICATION;

EID: 33745114356     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000219787.65915.56     Document Type: Article

References (33)

1. Wright S. Evolution in Mendelian populations. 1931. Bull Math Biol. 1990;52:241-295.
2. Mahalingam B, Louis JM, Reed CC, et al. Structural and kinetic analysis of drug resistant mutants of HIV-1 protease. Eur J Biochem. 1999;263:238-245.
3. Gulnik SV, Suvorov LI, Liu B, et al. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry. 1995;34:9282-9287.
4. Quinones-Mateu ME, Weber J, Rangel HR, et al. HIV-1 fitness and antiretroviral drug resistance. AIDS Rev. 2001;3:223-242.
5. Zhang YM, Imamichi H, Imamichi T, et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol. 1997;71:6662-6670.
6. Croteau G, Doyon L, Thibeault D, et al. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol. 1997;71:1089-1096.
7. Doyon L, Croteau G, Thibeault D, et al. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol. 1996;70:3763-3769.
8. Mammano F, Petit C, Clavel F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol. 1998;72:7632-7637.
9. Boden D, Markowitz M. Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother. 1998;42:2775-2783.
10. Cote HC, Brumme ZL, Harrigan PR. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J Virol. 2001;75:589-594.
11. Gatanaga H, Suzuki Y, Tsang H, et al. Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors. J Biol Chem. February 22, 2002;277(8):5952-5961.
12. Myint L, Matsuda M, Matsuda Z, et al. Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2004;48:444-452.
13. Nijhuis M, Schuurman R, de Jong D, et al. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS. 1999;13:2349-2359.
14. Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA. 2002 July 10;288(2):181-188.
15. Simon V, Vanderhoeven J, Hurley A, et al. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS. Jul 26, 2002;16(11):1511-1519.
16. Wensing AM, Boucher CA. Worldwide transmission of drug-resistant HIV. AIDS Rev. 2003;5:140-155.
17. Yerly S, Kaiser L, Race E, et al. Transmission of antiretroviral-drug- resistant HIV-1 variants. Lancet 1999;354:729-733.
18. Wensing AM, van de Vijver DA, Angarano G, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 2005;192:958-966.
19. Maschera B, Furfine E, Blair ED. Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors. J Virol. 1995;69:5431-5436.
20. Holland JJ, de la Torre JC, Clarke DK, et al. Quantitation of relative fitness and great adaptability of clonal populations of RNA viruses. J Virol. 1991;65:2960-2967.
21. Boom R, Sol CJ, Salimans MM, et al. Rapid and simple method for purification of nucleic acids. J Clin Microbiol. 1990;28:495-503.
22. Nijhuis M, Boucher CA, Schuurman R. Sensitive procedure for the amplification of HIV-1 RNA using a combined reverse-transcription and amplification reaction. Biotechniques. 1995;19:178-180, 182.
23. van Maarseveen NM, Huigen MC, de Jong D, et al. A novel real-time PCR assay to determine relative replication capacity for HIV-1 protease variants and/or reverse transcriptase variants. J Virol Methods. 2006;133(2):185-194.
24. Reed LJ, Muench H. A simple method for estimating fifty percent endpoints. Am J Hyg. 1983:493-497.
25. Baxter JD, Leduc RE, Leong H, et al. Prevalence of HIV-1 GAG cleavage site mutations in patients failing protease inhibitors in the GART study (CPCRA 046). Antivir Ther. 2004;9:S48.
26. Maguire MF, Guinea R, Griffin P, et al. Changes in human immunodeficiency virus type 1 gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J Virol. August 1, 2002;76:7398-7406.
27. Borman AM, Paulous S, Clavel F. Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. J Gen Virol. 1996;77(Pt 3):419-426.
28. Boeri E, Gianotti N, Canducci F, et al. Evolutionary characteristics of HIV type 1 variants resistant to protease inhibitors in the absence of drug-selective pressure. AIDS Res Hum Retroviruses. 2003;19:1151-1153.
29. Campo RE, Rosa I, Lichtenberger PN, et al. Effect of class-specific therapy interruption on persistence of HIV type 1 antiretroviral resistance. AIDS Res Hum Retroviruses. 2003;19:653-656.
30. Deeks SG, Hoh R, Neilands TB, et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis. 2005;192:1537-1544.
31. Barbour JD, Hecht FM, Wrin T, et al. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS. 2004;18:1683-1689.
32. Chan KC, Galli RA, Montaner JS, et al. Prolonged retention of drug resistance mutations and rapid disease progression in the absence of therapy after primary HIV infection. AIDS. 2003;17:1256-1258.
33. Pao D, Andrady U, Clarke J, et al. Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr. 2004;37:1570-1573.